Evidence map›Paper›PMID 38228681›Full record

ArticleLeukemia2024

Clonal medicine targeting DNA damage response eradicates leukemia.

Monika M Toma, Adam Karami, Margaret Nieborowska-Skorska, Kumaraswamy Naidu Chirtala, Monika Pepek, Emir Hadzijusufovic, Tomasz Stoklosa, Peter Valent, Tomasz Skorski

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Monika M TomaFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.
Adam KaramiFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.
Margaret Nieborowska-SkorskaFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.
Kumaraswamy Naidu ChirtalaFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.
Monika PepekDepartment of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.
Emir HadzijusufovicLudwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Tomasz StoklosaDepartment of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0001-6918-5056
Peter ValentLudwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0456-5095
Tomasz SkorskiFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA. tskorski@temple.edu.ORCID http://orcid.org/0000-0002-3809-4538

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
AML mutation-guided drugging of DNA repairR01CA237286 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI MAZIN, ALEXANDER V, SKORSKI, TOMASZ · 2020 to 2024
$2.8M
PolQ as a novel therapeutic target in AMLR01CA244179 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI POMERANTZ, RICHARD T, SKORSKI, TOMASZ · 2020 to 2024
$2.7M
MPN-inducing mutations as biomarkers of synthetic lethalityR01CA247707 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2020 to 2024
$2.1M
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitorsR01CA244044 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2020 to 2024
$1.9M
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA237286NCI NIH HHS R01 CA244044NCI NIH HHS R01 CA244179NCI NIH HHS R01 CA247707
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LeukemiaClone CellsDNA DamageDNA RepairHumans

Identifiers

PMID38228681
PMCPMC10912018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.